Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

Subjects:

Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

Subjects:

Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

Subjects:

Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

Tumor volume measurements. by Hedieh Zargaran (21410233)

DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

Relationship between the toxicity of organic solvents and their melting point. by Masahiro Tomioka (430683)

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... by Midhun Sebastian Jose (19336846)

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

电针预处理通过心肌缺血损伤 棕色脂肪组织和 BMP3b/Smad1/5 通路小鼠 by Danying Qian (21730250)

Subjects: “…electroacupuncture significantly decreased…”

Primer sequences used for RT-PCR. by Jingjing Chen (293564)

“…Notably, SIRT1 levels decrease with age in both mice and during cellular senescence, highlighting its significance in anti-aging processes. …”

Box plots showing the taxa that were significantly different between thin and normal cows. by Bhuripit Saraphol (20855573)

Subjects:

ELISA analysis revealed a significant decrease in SP (A & B) and CGRP (C & D) protein levels in the corneas and tear fluid of mice treated with 0.5% bupivacaine (BUP) every alternate day for 15 days (administered via subconjunctival injection (SCI) alone or in combination with topical (TOP) application) compared to PBS-treated controls. by Ananya Datta (19932144)